Condition: Relapse B Acute Lymphoblastic Leukemia · Refactory Childhood Acute Lymphoblastic Leukemia · Sponsor: Chulalongkorn University
A Phase 1 clinical trial to evaluate the safety and early efficacy of Chimeric Antigen Receptor T-cell (CAR T-cell) with IL-7Rα signaling targeting CD19 in children with relapsed and refractory B-cell Acute Lymphoblastic Leukemia (ALL) after complete standard treatments.
This description comes directly from the study's public registry record.
Piti Techavichit, Associate Professor, MD · +66817515363 · piti.t@chula.ac.th
Koramit Suppipat, MD · +66816282068 · koramit.s@chula.ac.th
Always discuss trial participation with your own doctor first.
| Siriraj Hospital | Bangkok, Bangkoknoi, Thailand | Not Yet Recruiting |
| Maharaj Nakorn Chiang Mai Hospital | Chiang Mai, Mueang Chiang Mai District, Thailand | Not Yet Recruiting |
| King Chulalongkorn Memorial Hospital | Bangkok, Pathumwan, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07078929